MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Class A Ordinary Shares (NQ: APLM )

0.1956 -0.0065 (-3.22%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 253,738
Open 0.2025
Bid (Size) 0.1942 (10)
Ask (Size) 0.2100 (121)
Prev. Close 0.2021
Today's Range 0.1942 - 0.2050
52wk Range 0.1805 - 6.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
From Apollomics Inc.
Via GlobeNewswire

Performance

YTD
-78.72%
-78.72%
1 Month
-4.86%
-4.86%
3 Month
-65.07%
-65.07%
6 Month
-80.39%
-80.39%
1 Year
-96.50%
-96.50%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
From Apollomics Inc.
Via GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
From Apollomics Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Via Talk Markets
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
From Apollomics Inc.
Via GlobeNewswire
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story